Cancer Synoptic Reporting Project Group
07 February 2022 at 17:30 UTC
Meeting Recording (GoogleDrive)
https://drive.google.com/file/d/1RGdxdmUBxUQVognh0EXwMximyTaBb40-1FVnrT3NjVwDiW_4G5oLZuBRA08fSOhB4/view?usp=sharing
Discussion items
| Item | Description | Owner | Notes | Action |
|---|---|---|---|---|
| 1 | IHC |
Note: This defers metastatic observable to the info model | a. her2 in breast tissue
b. her2 in breast cancer from lymph node
| |
| 2 | Treatment effect | Continue discussion: What are we measuring when assessing "treatment effect"? Is this a histologic change? Viability of tumor cells?
Note: SSA wonders about property in this model |
Will review model. This observable pertains to the process of regression/change in the neoplasm after antineoplastic therapy. So, observable could be modeled as presence of process changes. | |
| 3 | Lymph nodes |
2. Management of observables for lymph node involvement. Example: | Did not discuss | |
| 4 | AJCC update? | Any updates that can be shared? | Jim Case meeting with AJCC on Wednesday 26-Jan to continue/finalize contract issues |
Meeting Files
| Attachments |
|---|
Previous Meetings
| Content Report Table | ||||||||
|---|---|---|---|---|---|---|---|---|
|